key: cord-0918761-xd67nd6y authors: Shiakolas, Andrea R.; Kramer, Kevin J.; Wrapp, Daniel; Richardson, Simone I.; Schäfer, Alexandra; Wall, Steven; Wang, Nianshuang; Janowska, Katarzyna; Pilewski, Kelsey A.; Venkat, Rohit; Parks, Robert; Manamela, Nelia P.; Raju, Nagarajan; Fechter, Emilee Friedman; Holt, Clinton M.; Suryadevara, Naveenchandra; Chen, Rita E.; Martinez, David R.; Nargi, Rachel S.; Sutton, Rachel E.; Ledgerwood, Julie E.; Graham, Barney S.; Diamond, Michael S.; Haynes, Barton F.; Acharya, Priyamvada; Carnahan, Robert H.; Crowe, James E.; Baric, Ralph S.; Morris, Lynn; McLellan, Jason S.; Georgiev, Ivelin S. title: Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions date: 2021-05-21 journal: Cell Rep Med DOI: 10.1016/j.xcrm.2021.100313 sha: 2cfd955ced1678009b6233ae914622761cf5ab2e doc_id: 918761 cord_uid: xd67nd6y The continual emergence of novel coronavirus (CoV) strains, like SARS-CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a panel of six monoclonal antibodies that cross-react with CoV spike (S) proteins from the highly pathogenic SARS-CoV and SARS-CoV-2, and demonstrate a spectrum of reactivity against other CoV. Epitope mapping reveals that these antibodies recognize multiple epitopes on SARS-CoV-2 S, including the receptor binding domain, N-terminal domain, and S2 subunit. Functional characterization demonstrates that the antibodies mediate phagocytosis - and in some cases trogocytosis - but not neutralization in vitro. When tested in vivo in murine models, two of the antibodies demonstrate a reduction in hemorrhagic pathology in the lungs. The identification of cross-reactive epitopes recognized by functional antibodies expands the repertoire of targets for pan-coronavirus vaccine design strategies. The emergence of a novel coronavirus (CoV) SARS-CoV-2, the causative agent of COVID-19, 7 application of the LIBRA-seq technology enabled the identification of a panel of cross-reactive 137 antibodies that recognize the S antigen from multiple coronaviruses. 138 To elucidate the epitopes targeted by the cross-reactive antibodies, we performed binding 140 assays to various structural domains of S as well as binding-competition experiments. First, we 141 assessed antibody binding to the S1 and S2 subdomains of SARS-CoV-2. Antibodies 46472-1, 142 46472-2, 46472-3, and 46472-4 bound to the S2 domain, whereas 46472-6 and 46472-12 143 recognized the S1 domain but targeted different epitopes, the NTD and RBD, respectively 144 ( found that the S2-directed antibodies 46472-1, 46472-2, and 46472-4 competed for binding to S 149 ( Figure 2D ). This pattern was observed for both SARS-CoV-2 and SARS-CoV S. Of note, this 150 competition group did not include S2-directed antibody 46472-3, revealing the identification of 151 multiple cross-reactive epitope targets on S2 ( Figure 2D) . Further, antibody binding was not 152 affected by two glycan knockout mutants (N165A or N709A) or mannose competition 153 (Supplemental Figure 2E-F) . Lastly, we measured antibody autoreactivity, and found that with 154 the exception of 46472-6 binding to Jo-1, none of the antibodies showed autoreactivity against 155 the tested antigens ( Figure 2E ). Together, these data suggest that the identified cross-reactive 156 antibodies are coronavirus-specific and target multiple, diverse epitopes on the S protein 157 ( Figure 2F) . 158 Next, we characterized our cross-reactive antibody panel for functional activity. Although none 160 of the antibodies neutralized SARS-CoV or SARS-CoV-2 (Supplemental Figure 3A- Figure 3A ). In particular, the RBD-reactive antibody 46472-12 showed greater ADCP activity 163 compared to the other cross-reactive antibodies and the SARS-CoV/SARS-CoV-2 cross-164 reactive RBD antibody control, CR3022 28 ( Figure 3A, Supplemental Figure 3C) . Further, we 165 tested and confirmed ADCP activity against SARS-CoV for two antibodies that mediated the 166 highest phagocytotic activity against SARS-CoV-2, 46472-4 and 46472-12, illustrating that these 167 antibodies have cross-coronavirus phagocytic ability ( Figure 3B, Supplemental Figure 3D ). 168 We next tested the antibodies in a trogocytosis assay 29 control CR3022, and all three groups were significantly lower than the scores for isotype control 182 DENV-2D22 (p<0.01, ordinary one-way ANOVA with multiple comparisons) ( Figure 4B , 183 Supplemental Figure 4A ). To evaluate the in vivo effect of these antibodies in a more stringent 184 challenge model in 12-month old female BALB/c mice, we increased the viral dose from 1x10 3 185 to 1x10 4 PFU. In this experiment, mice that received antibody 46472-12 exhibited the best 186 survival rate (4/5 at day 4), compared to the other treatment groups that included CR3022 as an 187 antigen-specific control and DENV-2D22 as a negative control, although statistical significance 188 J o u r n a l P r e -p r o o f 9 was not achieved (Figure 4C-D, Supplemental Figure 4B ). There were no significant 189 differences in viral load between groups; however, the surviving animals from the 46472-4 and 190 46472-12 groups showed significantly lower hemorrhagic pathology scores in harvested mouse 191 lungs compared to the negative control treatment group (p<0.001, ordinary one-way ANOVA 192 with multiple comparisons) ( Figure 4C ). Animals treated with the antigen-specific control, 193 CR3022, had significantly higher hemorrhage scores than animals treated with 46472-4 and Here, we described a set of cross-reactive Betacoronavirus antibodies isolated from a 202 recovered SARS-CoV donor. The antibodies targeted diverse epitopes on S, including the S2 203 subdomain as well as the RBD and NTD on S1, and demonstrated Fc effector function in vitro. 204 Additionally, two of these antibodies were tested in vivo, and displayed a reduction in lung 205 hemorrhage score, while effects on viral load were not definitive. 206 Given the similar effect of 46472-4 and 46472-12 on severe disease in the mouse model, their 207 phagocytotic ability along with the inability to mediate neutralization suggests that the former 208 may be a mechanism through which they function, and additional studies are underway to 209 further assess this hypothesis. Phagocytosis has been shown to be associated with protection 210 in a SARS-CoV-2 DNA vaccination in non-human primates as well as survival in natural 211 infection 33 and as such could be an important mechanism for protection by monoclonal 212 antibodies. The role of trogocytosis in COVID-19 is unknown as are the targets that may be 213 important for this function. 46472-4 was able to mediate this membrane nibbling in contrast to 214 46472-12, suggesting that this function in addition to complement activity was not responsible 215 for the in vivo effect on severe disease mediated by these antibodies. Although the precise in 216 vivo effects of these antibodies have not been elucidated, the identification of multiple, cross-217 reactive antibodies highlights a potential role for Fc effector function activity, specifically We utilized and modified our previously described pipeline to use paired-end FASTQ files of 524 oligo libraries as input, process and annotate reads for cell barcode, UMI, and antigen barcode, 525 and generate a cell barcode -antigen barcode UMI count matrix 27 . BCR contigs were processed 526 using Cell Ranger (10X Genomics) using GRCh38 as reference. Antigen barcode libraries were 527 also processed using Cell Ranger (10X Genomics). The overlapping cell barcodes between the 528 two libraries were used as the basis of the subsequent analysis. We removed cell barcodes that 529 had only non-functional heavy chain sequences as well as cells with multiple functional heavy 530 chain sequences and/or multiple functional light chain sequences, reasoning that these may be 531 multiplets. Additionally, we aligned the BCR contigs (filtered_contigs.fasta file output by Cell 532 Ranger, 10X Genomics) to IMGT reference genes using HighV-Quest 46 . The output of HighV-533 Quest was parsed using ChangeO 47 and merged with an antigen barcode UMI count matrix. 534 Finally, we determined the LIBRA-seq score for each antigen in the library for every cell as To assess antibody binding, soluble protein was plated at 2 µg/ml overnight at 4°C. The next 579 day, plates were washed three times with PBS supplemented with 0.05% Tween-20 (PBS-T) 580 and coated with 5% milk powder in PBS-T. Plates were incubated for one hour at room 581 temperature and then washed three times with PBS-T. Primary antibodies were diluted in 1% 582 milk in PBS-T, starting at 10 µg/ml with a serial 1:5 dilution and then added to the plate. The 583 plates were incubated at room temperature for one hour and then washed three times in PBS-T. 584 The secondary antibody, goat anti-human IgG conjugated to peroxidase, was added at 1:10,000 585 dilution in 1% milk in PBS-T to the plates, which were incubated for one hour at room 586 temperature. Goat anti-mouse secondary was used for SARS-CoV specific control antibody 587 240CD (BEI Resources). Plates were washed three times with PBS-T and then developed by 588 adding TMB substrate to each well. The plates were incubated at room temperature for ten 589 minutes, and then 1N sulfuric acid was added to stop the reaction. Plates were read at 450 nm. Competition ELISAs were performed as described above, with some modifications. After coating 597 with antigen and blocking, 25 µl of non-biotinylated competitor antibody was added to each well 598 at 10 µg/ml and incubated at 37°C for 10 minutes. Then, without washing, 75 µl biotinylated 599 antibody (final concentration of 1 µg/ml) was added and incubated at 37°C for 1 hour. After 600 washing three times with PBS-T, streptavidin-HRP was added at 1:10,000 dilution in 1% milk in 601 PBS-T and incubated for 1 hour at room temperature. Plates were washed and substrate and 602 sulfuric acid were added as described above. ELISAs were repeated at least 2 times. Data is 603 shown as the % decrease in binding. 604 605 Autoreactivity 606 Monoclonal antibody reactivity to nine autoantigens (SSA/Ro, SS-B/La, Sm, ribonucleoprotein 607 (RNP), Scl 70, Jo-1, dsDNA, centromere B, and histone) was measured using the AtheNA Multi-608 Lyte® ANA-II Plus test kit (Zeus scientific, Inc, #A21101). Antibodies were incubated with 609 AtheNA beads for 30min at concentrations of 50, 25, 12.5 and 6.25 µg/mL. Beads were 610 washed, incubated with secondary and read on the Luminex platform as specified in the kit 611 protocol. Data were analyzed using AtheNA software. Positive (+) specimens received a score 612 >120, and negative (-) specimens received a score <100. Samples between 100-120 were 613 considered indeterminate. 614 615 Mannose competition ELISAs were performed as described above with minor modifications. 617 After antigen coating and washing, nonspecific binding was blocked by incubation with 5% FBS 618 diluted in PBS for 1 hour at RT. Primary antibodies were diluted in 5% FBS-PBST +/-1M D-(+)-619 Mannose starting at 10 µg/ml with a serial 1:5 dilution and then added to the plate for 1 hour at 620 RT. After washing, antibody binding was detected with goat anti-human IgG conjugated to 621 peroxidase and added at 1:10,000 dilution in 5% FBS in PBS-T to the plates. After 1 hour 622 46472-4 46472-12 CR3022 DENV-2D22 load titers and hemorrhage scores from animal experiments using GraphPad Prism version 750 8.0.0. Details of the statistical analyses can be found in the main text and figure captions Genomic characterisation and epidemiology of 2019 novel coronavirus: 784 implications for virus origins and receptor binding Recombination, Reservoirs, and the Modular 786 Mechanisms of Coronavirus Cross-Species Transmission The 788 Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional 789 Characterization of the Fusion Core Complex Structural insights into coronavirus entry Cryo-EM structure of the 2019-nCoV spike in the 794 prefusion conformation Neutralizing Antibodies against SARS-CoV-2 796 and Other Human Coronaviruses SARS-CoV-2 vaccines in development Structure, Function, and Evolution of Coronavirus Spike Proteins Potent 802 neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability A neutralizing human antibody binds to the N-terminal domain of 806 the Spike protein of SARS-CoV-2 Rapid isolation and profiling of 809 a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike 810 protein Cross-neutralization of SARS-CoV-2 by 813 a human monoclonal SARS-CoV antibody Isolation of potent SARS-CoV-2 neutralizing 816 antibodies and protection from disease in a small animal model CoV555 in Outpatients with Covid-19 Monoclonal Antibodies to Disrupt Progression of Early Covid-19 REGN-COV2, a Neutralizing Antibody 824 Outpatients with Covid-19 CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity SARS-related viruses by human monoclonal antibodies Cross-reactive Antibody Response 834 between SARS-CoV-2 and SARS-CoV Infections Dissecting antibody-mediated protection against SARS-836 Preexisting and de novo humoral 839 immunity to SARS-CoV-2 in humans Phagocytic cells contribute to the 842 antibody-mediated elimination of pulmonary-infected SARS coronavirus Antibody 846 potency, effector function, and combinations in protection and therapy for SARS-CoV-2 847 infection in vivo Distinct Early Serological Signatures Track 850 with SARS-CoV-2 Survival Evolution of Early SARS-CoV-2 and 853 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its 856 immune cross-reactivity with SARS-CoV Mapping of B Cell Receptor Sequences to Antigen Specificity A highly conserved cryptic epitope in the receptor binding domains of SARS-862 Measuring the ability 864 of HIV-specific antibodies to mediate trogocytosis A mouse-adapted 868 model of SARS-CoV-2 to test COVID-19 countermeasures A Mouse-Adapted SARS-CoV Induces Acute Lung Injury and Mortality in Standard Laboratory Mice DNA vaccine protection 875 against SARS-CoV-2 in rhesus macaques Dissecting antibody-mediated protection against SARS-877 Dissecting strategies to tune the 880 therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022 Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for 884 Differential 886 requirements for FcγR engagement by protective antibodies against Ebola virus Broadly neutralizing 889 anti-influenza antibodies require Fc receptor engagement for in vivo protection Beyond binding: antibody 892 effector functions in infectious diseases Human neutralizing antibodies against SARS-895 CoV-2 require intact Fc effector functions for optimal therapeutic protection Swine acute diarrhea 899 syndrome coronavirus replication in primary human cells reveals potential susceptibility 900 to infection CoV poised for human emergence A SARS-like cluster 906 of circulating bat coronaviruses shows potential for human emergence From SARS to MERS, Thrusting Coronaviruses into the Spotlight Compromised Humoral Functional Evolution 913 Tracks with SARS-CoV-2 Mortality Immunogenicity and 916 structures of a rationally designed prefusion MERS-CoV spike antigen IMGT/V-QUEST and IMGT/HighV-921 QUEST for NGS Change-O: a toolkit for analyzing large-scale B cell 924 immunoglobulin repertoire sequencing data Enhancing dengue virus maturation using a stable furin over-927 expressing cell line Reverse 930 genetics with a full-length infectious cDNA of the Middle East respiratory syndrome 931 coronavirus Reverse genetics with a full-length 934 A robust, high-throughput 938 assay to determine the phagocytic activity of clinical antibody samples A high-throughput, bead-based, antigen-specific assay to assess the 942 ability of antibodies to induce complement activation The EMBL-EBI search and 946 sequence analysis tools APIs in 2019 Amino acid substitution matrices from protein 948 blocks Using Monovalent Phage Display Unexpected Receptor Functional 953 Mimicry Elucidates Activation of Coronavirus Fusion Identification of human 956 neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution incubation, plates were washed and substrate and sulfuric acid were added as described above. 623Data shown is representative of three replicates. 624 625 Epitope Mapping Visualization 626 SARS-CoV-2 Spike (PDB-6VSB) was visualized using PyMOL software. Antibody epitopes 627 were visualized on the SARS-CoV-2 spike using a structure of the pre-fusion stabilized SARS-628CoV-2 S-2P construct 5 modeled in the molecular graphics software PyMOL (The PyMOL 629 Molecular Graphics System, Version 2.3.5 Schrödinger, LLC). 630 To assess for neutralizing activity against SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 633 (obtained from the Centers for Disease Control and Prevention, a gift from N. Thornburg), we 634 used the high-throughput RTCA assay and xCelligence RTCA HT Analyzer (ACEA Biosciences) 635 that has been described previously 11 . After obtaining a background reading of a 384-well E-636 plate, 6,000 Vero-furin cells 48 were seeded per well. Sensograms were visualized using RTCA 637 Antibody-virus complexes were incubated at 37C with 5% CO2 for 1 hour. Following incubation, 655 growth media was removed and virus-antibody dilution complexes were added to the cells in 656 duplicate. Virus-only controls and cell-only controls were included in each neutralization assay 657 plate. Following infection, plates were incubated at 37C with 5% CO2 for 48 hours. After the 48 658 hour incubation, cells were lysed and luciferase activity was measured via Nano-Glo Luciferase 659Assay System (Promega) according to the manufacturer specifications. SARS-CoV and SARS-660CoV-2 neutralization titers were defined as the sample dilution at which a 50% reduction in RLU 661 was observed relative to the average of the virus control wells. 662 663 SPR 664His-tagged SARS-CoV-2 RBD-SD1 was immobilized to a NiNTA sensorchip to a level of ~150 665 RUs using a Biacore X100. Serial dilutions of purified Fab 46472-12 were evaluated for binding, 666 ranging in concentration from 1 to 0.25 µM. The resulting data were fit to a 1:1 binding model 667 using Biacore Evaluation Software. 668 Antibody-dependent cellular phagocytosis (ADCP) was performed using biotinylated SARS-671CoV-2 or SARS-CoV S coated fluorescent neutravidin beads as previously described 51 12 hours prior to virus inoculation. The next day, mice were administered intranasally with 1x10 3 705 PFU or 1x10 4 PFU of SARS-CoV-2 MA10, respectively. Mice were monitored daily for weight 706 loss, morbidity, and mortality, and after four days, mice were sacrificed and lung tissue was 707 harvested for viral titer as measured by plaque assays. One lung lobe was taken for 708 pathological analysis and the other lobe was processed for qPCR and viral load determination 709 as previously described 31 . For viral plaque assays, the caudal lobe of the right lung was 710 homogenized in PBS, and the tissue homogenate was then serial-diluted onto confluent 711 monolayers of Vero